Initial CDK 4/6 Inhibitor Plus Endocrine Therapy Versus Initial Chemotherapy in HR Positive, HER2 Negative Unresectable or Metastatic Breast Cancer

A Phase II Study to Evaluate the Efficacy and Safety of Anti-HER2 Triple-targeted Drugs Combined With CDK4/6 Inhibitors in Neoadjuvant Therapy for ER-positive HER2-positive Breast Cancer Patients.

NCT07290166 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

Anti-HER2 Therapy + Fulvestrant/Capecitabine in Women With HR+, HER2+, Non-visceral Metastases Stage IV Breast Cancer

NCT04337658 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3

Maintenance Therapy in HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer: A Phase II Study

NCT07179939 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

Real-World Study of Post-Resistance Treatment Strategies in Advanced Breast Cancer Following CDK4/6i, PIK3CA Inhibitors, or T-DXd

NCT07073755 ·Status: RECRUITING

Efficacy and Safety of CDK4/6 Inhibitors Combined With Endocrine Therapy in HR+/HER2- Neoadjuvant Therapy for Early Breast Cancer

NCT07130643 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Neoadjuvant Dose-dense Chemotherapy for HR+/HER2- Breast Cancer Patients With High Proliferation Index

NCT05728268 ·Status: RECRUITING ·Phase: PHASE2

A Multicenter Prospective Cohort Study of Adjuvant Therapy for BRCA1/2 Mutated Hormone Receptor-positive HER2-negative Early High-risk Breast Cancer

NCT06791161 ·Status: ENROLLING_BY_INVITATION

Study of Preoperative Chemotherapy for Early Triple Negative or HER2-positive Operable Breast Cancer

NCT02934828 ·Status: UNKNOWN ·Phase: PHASE2

Study of High-dose Chemotherapy (HDC) Combined With Adoptive Cellular Therapy With DC-CIK Cells in Triple Negative Breast Cancer Patients

NCT01232062 ·Status: COMPLETED

Neoadjuvant Therapy Study Guided by Drug Screening in Vitro for Human Epidermal Growth Factor Receptor 2 (HER2) Negative Early Breast Cancer Patients

NCT04836156 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

Neoadjuvant With Trastuzumab, Pyrotinib Plus Palbociclib and Fulvestrant in HER2-positive, ER-positive Breast Cancer

NCT05076695 ·Status: UNKNOWN ·Phase: PHASE2

Neoadjuvant Chemotherapy With Pyrotinib, Epirubicin and Cyclophosphamide Followed by Taxanes and Trastuzumab for HER-2+ Breast Cancer

NCT04290793 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2/PHASE3

Four Cycles Taxane With Trastuzumab and Pertuzumab Neoadjuvant Therapy Among Low Risk HER2 Positive Patients

NCT06722599 ·Status: RECRUITING

CTC Changes and Efficacy of Neoadjuvant Chemotherapy for Triple-negative Breast Cancer

NCT04059003 ·Status: UNKNOWN

Trastuzumab Combined With Pyrrolidine and Chemotherapy for Locally HER2 Positive Breast Cancer

NCT04481932 ·Status: RECRUITING ·Phase: PHASE2

Risk and Clinical Benefit of Chemotherapy and Intensive Endocrine Therapy for Luminal B1 Early-stage Breast Cancer

NCT03373708 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3

Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Chemotherapy in Patients With HER2 Positive Breast Cancer

NCT03847818 ·Status: UNKNOWN ·Phase: NA

Neoadjuvant Chemo-endocrine Therapy Versus Chemotherapy Alone in ER-positive, HER2-negative Breast Cancer

NCT02980965 ·Status: COMPLETED ·Phase: PHASE3

Real-world Effectiveness and Safety Study of T-Dxd in Chinese Metastatic Breast Cancer

NCT05594082 ·Status: UNKNOWN

To Identify Primary Resistance to CDK4/6 Inhibitors in Breast Cancer

NCT04660435 ·Status: RECRUITING

Neoadjuvant Chemotherapy + PD-1 Inhibitor+Different Radiotherapy Fractionations for HR+/HER2- Breast Cancer

NCT06639672 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

A Trial Comparing Docetaxel Plus Fulvestrant With Docetaxel in Metastatic Breast Cancer

NCT02137083 ·Status: COMPLETED ·Phase: PHASE2

Minus Anthracycline or Short-Term Versus Epirubicin and Cyclophosphamide Followed by Paclitaxel Regimen for Adjuvant Breast Cancer Therapy

NCT01314833 ·Status: COMPLETED ·Phase: PHASE3

Efficacy of T-Dxd in the Treatment of HER2-positive BCBM After Prior Pyrotinib

NCT06135194 ·Status: RECRUITING

Markers to Evaluate the Efficacy of PH-based Regimen as a Neoadjuvant Therapy for Operable HER2 Positive Breast Cancer

NCT04281641 ·Status: RECRUITING ·Phase: NA